Revolutionary nanotechnology illuminates brain cells at work

Until now it has been impossible to accurately measure the levels of important chemicals in living brain cells in real time and at the level of a single cell. Scientists at the Carnegie Institution's Department of Plant Biology and Stanford University are the first to overcome this obstacle by successfully applying genetic nanotechnology using molecular sensors to view changes in brain chemical levels. The sensors alter their 3-dimensional form upon binding with the chemical, which is then visible via a process known as fluorescence resonance energy transfer, or FRET. In a new study, the nanosensors were introduced into nerve cells to measure the release of the neurotransmitter glutamate -- the major brain chemical that increases nerve-cell activity in mammalian brains.

It is involved in everything from learning and memory to mood and perception. Too much glutamate is believed to contribute to conditions such as Alzheimer's and Parkinson's disease. The research is published in the May 30-June 3 on-line early edition of the Proceedings of the National Academy of Sciences.

"The fluorescent imaging technique allows us to see living cells do their jobs live and in color," explained Sakiko Okumoto, lead author of the study at Carnegie. "Understanding when and how glutamate is produced, secreted, reabsorbed, and metabolized in individual brain cells, in real time, will help researchers better understand disease processes and construct new drugs."

"FRET is like two musical tuning forks, which have the same tone," Okumoto continued. "If you excite one, it gives a characteristic tone. If you bring the second fork close to the first one, it will also start to give you a tone even though they do not touch. This is resonance energy transfer."

FRET is used to track the form of proteins that specifically bind metabolites such as sugars and amino acids. A protein of interest is genetically fused with two differently colored tags made from variants of the jellyfish Green Fluorescent Protein (GFP). The colored tags are placed at each end of the molecule making a "biosensor." When the substance of interest binds to the sensor, the sensor backbone becomes reoriented, and the reorientation can be detected. Since light is a vibration, the same response occurs with two fluorescent dyes that have overlapping, but slightly different colors–in this case cyan and yellow versions of GFP. The cyan is excited and, if the distance between the colored proteins changes, more or less energy is transferred to the yellow protein. In this study, the cyan and yellow proteins behave as if they move away from one another when the sensor recognizes glutamate. Thus, there is more cyan and less yellow light than in the absence of glutamate. The sensors are encoded by genes and genetic ZIP codes can be used to target the sensors to any location in the cell and to its surface.

"We used a protein called ybeJ from the common bacterium E. coli. We first predicted the structure of this protein, and then placed the two fluorophores at specific positions on the binding protein," commented co-author Loren Looger. "After fusion to the fluorescent proteins, we placed the sensor on the surface of rat hippocampal cells. The hippocampus is the part of the brain that is involved with emotional reactions, and it helps store learned information in memory. When neurons are activated, they secrete glutamate, and we could see this activity under the microscope by watching the color change. We stimulated the neurons and watched them secrete glutamate in response. We also saw the removal of the glutamate as the neurons returned to normal ready to fire again."

"This is a tremendously exciting technology," remarked Wolf Frommer, leader of the FRET team at Carnegie. "I'm anxious to see what we can learn about the vast complexities of the brain over the coming years, such as the role of glial cells in the process of glutamate removal from the synaptic cleft. It's fascinating to see a tool that we are using in plant biology open new areas in neuroscience."

Related link: Carnegie Institution Department of Plant Biology

Source: Carnegie Institution

Related stories:

Neurotransmitter defect may trigger autoimmune disease
A potentially blinding neurological disorder, often confused with multiple sclerosis (MS), has now become a little less mysterious. A new study by researchers at the Mayo Clinic in Rochester, Minnesota, may have uncovered the cause of Devic's disease. Their new study, which will appear online on October 6th in the Journal of Experimental Medicine, could result in new treatment options for this devastating disease.
Researchers identify novel mechanism to reduce nervous system inflammation
Researchers at Georgetown University Medical Center have discovered a new way to limit inflammation caused by the activation of microglia - key immune cells in the brain. Although the role of such cells is to "clean up damage" after injury, they often worsen the damage by releasing toxic inflammatory factors.
Study confirms benefit of combination therapy for Alzheimer's disease
Extended treatment with Alzheimer's disease drugs can significantly slow the rate at which the disorder advances, and combination therapy with two different classes of drugs is even better at helping patients maintain their ability to perform daily activities. Results from the first long-term study of the real-world use of Alzheimer's drugs, published by researchers from Massachusetts General Hospital in the July/September issue of Alzheimer Disease and Associated Disorders, support a level of effectiveness that may not be immediately apparent to patients or their family members.
The first autism disease genes
The autistic disorder was first described, more than sixty years ago, by Dr. Leo Kanner of the Johns Hopkins Hospital (USA), who created the new label 'early infantile autism'. At the same time an Austrian scientist, Dr. Hans Asperger, described a milder form of the disorder that became known as Asperger Syndrome, characterised by higher cognitive abilities and more normal language function. Today, both disorders are classified in the continuum of 'Pervasive Developmental Disorders' (PDD), more often referred to as Autism Spectrum Disorders (ASD).
Inherited form of hearing loss stems from gene mutation
Pat Phalin learned she had hearing loss at 30, when she volunteered to give hearing tests at her local school. The pupils heard sounds she could not hear.
Scientists find how neural activity spurs blood flow in the brain
New research from Harvard University neuroscientists has pinpointed exactly how neural activity boosts blood flow to the brain. The finding has important implications for our understanding of common brain imaging techniques such as fMRI, which uses blood flow in the brain as a proxy for neural activity.
Researchers uncover mechanism of action of antibiotic able to reduce neuronal cell death in brain
Virginia Commonwealth University researchers have discovered how an antibiotic works to modulate the activity of a neurotransmitter that regulates brain functions, which eventually could lead to therapies to treat Alzheimer’s disease, Huntington’s disease, epilepsy, stroke, dementia and malignant gliomas.
New brain cells implicated in machinery of cannabinoid signaling
The brain cells called astrocytes, and not just neurons, are sensitive to the substances called cannabinoids—the active chemicals in marijuana.

News discussion:

Nanotechnology news